Symbols / AGIO
AGIO Chart
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.78B |
| Enterprise Value | 966.40M | Income | -412.78M | Sales | 54.03M |
| Book/sh | 20.41 | Cash/sh | 14.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 539 | IPO | — |
| P/E | — | Forward P/E | -6.14 | PEG | — |
| P/S | 32.96 | P/B | 1.49 | P/C | — |
| EV/EBITDA | -2.07 | EV/Sales | 17.89 | Quick Ratio | 10.53 |
| Current Ratio | 11.46 | Debt/Eq | 3.37 | LT Debt/Eq | — |
| EPS (ttm) | -7.12 | EPS next Y | -4.95 | EPS Growth | — |
| Revenue Growth | 86.10% | Earnings | 2026-04-30 | ROA | -19.93% |
| ROE | -30.20% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -6.09% | Profit Margin | 0.00% | Shs Outstand | 58.59M |
| Shs Float | 49.38M | Short Float | 11.62% | Short Ratio | 7.08 |
| Short Interest | — | 52W High | 46.00 | 52W Low | 22.24 |
| Beta | 0.91 | Avg Volume | 1.27M | Volume | 1.18M |
| Target Price | $38.88 | Recom | Buy | Prev Close | $30.20 |
| Price | $30.39 | Change | 0.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.88
Mean price target
2. Current target
$30.39
Latest analyst target
3. DCF / Fair value
$-82.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.39
Low
$28.00
High
$65.00
Mean
$38.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-12 | main | HC Wainwright & Co. | Buy → Buy | $65 |
| 2026-01-06 | main | JP Morgan | Neutral → Neutral | $25 |
| 2025-12-26 | main | Leerink Partners | Outperform → Outperform | $40 |
| 2025-12-24 | main | Truist Securities | Buy → Buy | $38 |
| 2025-12-24 | main | B of A Securities | Buy → Buy | $34 |
| 2025-12-24 | main | HC Wainwright & Co. | Buy → Buy | $62 |
| 2025-11-26 | init | Citigroup | — → Buy | $38 |
| 2025-11-24 | init | Truist Securities | — → Buy | $32 |
| 2025-11-21 | main | JP Morgan | Neutral → Neutral | $20 |
| 2025-11-20 | down | RBC Capital | Outperform → Sector Perform | $28 |
| 2025-11-20 | main | B of A Securities | Buy → Buy | $32 |
| 2025-11-20 | up | Leerink Partners | Market Perform → Outperform | $34 |
| 2025-11-20 | main | Goldman Sachs | Neutral → Neutral | $25 |
| 2025-11-20 | main | HC Wainwright & Co. | Buy → Buy | $48 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $56 |
| 2025-07-28 | main | Scotiabank | Sector Outperform → Sector Outperform | $65 |
| 2025-07-22 | main | B of A Securities | Buy → Buy | $51 |
| 2025-05-02 | main | Scotiabank | Sector Outperform → Sector Outperform | $71 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $58 |
| 2024-12-18 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
- Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: A 28.73% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews ue, 24 Feb 2026 15
- Understanding Momentum Shifts in (AGIO) - Stock Traders Daily Mon, 23 Feb 2026 02
- Agios Pharmaceuticals (AGIO) Valuation Check After 2025 Results And New Shelf Registration Filing - simplywall.st Mon, 23 Feb 2026 09
- From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - The Globe and Mail Mon, 23 Feb 2026 08
- This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily Wed, 19 Nov 2025 08
- Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - The Motley Fool ue, 17 Feb 2026 08
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance hu, 05 Feb 2026 08
- Agios stock rebounds as Leerink upgrades (AGIO:NASDAQ) - Seeking Alpha hu, 20 Nov 2025 08
- Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESMEâ„¢ for Thalassemia - Quiver Quantitative hu, 12 Feb 2026 08
- Agios Pharmaceuticals stock tumbles after mixed sickle cell trial results - Investing.com Wed, 19 Nov 2025 08
- Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance hu, 12 Feb 2026 08
- Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool Wed, 19 Nov 2025 08
- Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook - The Globe and Mail Sat, 14 Feb 2026 08
- AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Yahoo Finance hu, 20 Nov 2025 08
- Agios Pharmaceuticals (AGIO) Valuation Check As Shares Trade Near Recent Levels And PYRUKYND Prospects Evolve - simplywall.st Sat, 14 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2872 | 77601.0 | — | Sale at price 27.02 per share. | MILANOVA TSVETA | Officer | — | 2026-01-05 00:00:00 | D |
| 1 | 8475 | nan | — | — | MILANOVA TSVETA | Officer | — | 2026-01-05 00:00:00 | D |
| 2 | 18703 | 506664.0 | — | Sale at price 27.09 per share. | GOFF BRIAN | Chief Executive Officer | — | 2025-12-30 00:00:00 | D |
| 3 | 38278 | nan | — | — | GOFF BRIAN | Chief Executive Officer | — | 2025-12-30 00:00:00 | D |
| 4 | 2932 | 79428.0 | — | Sale at price 27.09 per share. | MILANOVA TSVETA | Officer | — | 2025-12-30 00:00:00 | D |
| 5 | 6000 | nan | — | — | MILANOVA TSVETA | Officer | — | 2025-12-30 00:00:00 | D |
| 6 | 2932 | 79428.0 | — | Sale at price 27.09 per share. | JONES CECILIA | Chief Financial Officer | — | 2025-12-30 00:00:00 | D |
| 7 | 6000 | nan | — | — | JONES CECILIA | Chief Financial Officer | — | 2025-12-30 00:00:00 | D |
| 8 | 2932 | 79428.0 | — | Sale at price 27.09 per share. | GHEUENS SARAH | Officer | — | 2025-12-30 00:00:00 | D |
| 9 | 6000 | nan | — | — | GHEUENS SARAH | Officer | — | 2025-12-30 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 67.12M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.06 | 0.00 | 0.00 |
| NormalizedEBITDA | -466.95M | -1.51B | -384.86M | -518.19M |
| TotalUnusualItems | 0.00 | 1.09B | 0.00 | 137.70M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 1.09B | 0.00 | 137.70M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -412.78M | 673.73M | -352.09M | -231.80M |
| ReconciledDepreciation | 5.18M | 5.65M | 6.62M | 8.56M |
| ReconciledCostOfRevenue | 6.34M | 4.17M | 2.88M | 1.70M |
| EBITDA | -466.95M | -420.08M | -384.86M | -380.48M |
| EBIT | -472.13M | -425.74M | -391.49M | -389.05M |
| NetInterestIncome | 56.38M | 48.08M | 33.34M | 12.79M |
| InterestIncome | 56.38M | 48.08M | 33.34M | 12.79M |
| NormalizedIncome | -412.78M | -348.29M | -352.09M | -369.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -412.78M | 673.73M | -352.09M | -231.80M |
| TotalExpenses | 526.16M | 462.24M | 418.31M | 403.29M |
| TotalOperatingIncomeAsReported | -472.13M | -425.74M | -391.49M | -389.05M |
| DilutedAverageShares | 57.97M | 57.89M | 55.65M | 54.79M |
| BasicAverageShares | 57.97M | 56.81M | 55.65M | 54.79M |
| DilutedEPS | -7.12 | 11.64 | -6.33 | -4.23 |
| BasicEPS | -7.12 | 11.86 | -6.33 | -4.23 |
| DilutedNIAvailtoComStockholders | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncomeCommonStockholders | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncome | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncomeIncludingNoncontrollingInterests | -412.78M | 673.73M | -352.09M | -231.80M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | 1.96B | |
| NetIncomeContinuousOperations | -412.78M | 673.73M | -352.09M | -231.80M |
| TaxProvision | -1.02M | 44.24M | 0.00 | 0.00 |
| PretaxIncome | -413.80M | 717.97M | -352.09M | -231.80M |
| OtherIncomeExpense | 1.96M | 1.10B | 6.05M | 144.45M |
| OtherNonOperatingIncomeExpenses | 1.96M | 6.49M | 6.05M | 6.75M |
| SpecialIncomeCharges | 0.00 | 1.09B | 0.00 | 137.70M |
| GainOnSaleOfBusiness | 0.00 | 1.09B | 0.00 | 137.70M |
| RestructuringAndMergernAcquisition | -127.85M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 56.38M | 48.08M | 33.34M | 12.79M |
| TotalOtherFinanceCost | -12.79M | -836.00K | ||
| InterestIncomeNonOperating | 56.38M | 48.08M | 33.34M | 12.79M |
| OperatingIncome | -472.13M | -425.74M | -391.49M | -389.05M |
| OperatingExpense | 519.82M | 458.07M | 415.43M | 401.58M |
| ResearchAndDevelopment | 339.54M | 301.29M | 295.53M | 279.91M |
| SellingGeneralAndAdministration | 180.28M | 156.78M | 119.90M | 121.67M |
| GrossProfit | 47.68M | 32.33M | 23.94M | 12.54M |
| CostOfRevenue | 6.34M | 4.17M | 2.88M | 1.70M |
| TotalRevenue | 54.03M | 36.50M | 26.82M | 14.24M |
| OperatingRevenue | 54.03M | 36.50M | 26.82M | 14.24M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 16.22M | 16.22M | 16.22M | 16.22M |
| OrdinarySharesNumber | 58.45M | 57.16M | 55.95M | 55.04M |
| ShareIssued | 74.67M | 73.37M | 72.16M | 71.26M |
| TotalDebt | 40.21M | 56.99M | 72.00M | 85.66M |
| TangibleBookValue | 1.19B | 1.54B | 811.02M | 1.10B |
| InvestedCapital | 1.19B | 1.54B | 811.02M | 1.10B |
| WorkingCapital | 859.85M | 884.44M | 765.88M | 770.14M |
| NetTangibleAssets | 1.19B | 1.54B | 811.02M | 1.10B |
| CapitalLeaseObligations | 40.21M | 56.99M | 72.00M | 85.66M |
| CommonStockEquity | 1.19B | 1.54B | 811.02M | 1.10B |
| TotalCapitalization | 1.19B | 1.54B | 811.02M | 1.10B |
| TotalEquityGrossMinorityInterest | 1.19B | 1.54B | 811.02M | 1.10B |
| StockholdersEquity | 1.19B | 1.54B | 811.02M | 1.10B |
| GainsLossesNotAffectingRetainedEarnings | 2.19M | -1.52M | -441.00K | -12.54M |
| OtherEquityAdjustments | 2.19M | -1.52M | -441.00K | -12.54M |
| TreasuryStock | 802.49M | 802.49M | 802.49M | 802.49M |
| RetainedEarnings | -561.71M | -148.92M | -822.65M | -470.56M |
| AdditionalPaidInCapital | 2.56B | 2.49B | 2.44B | 2.39B |
| CapitalStock | 75.00K | 73.00K | 72.00K | 71.00K |
| CommonStock | 75.00K | 73.00K | 72.00K | 71.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 104.11M | 122.24M | 126.10M | 137.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.91M | 41.09M | 58.14M | 75.28M |
| OtherNonCurrentLiabilities | 90.00K | 880.00K | 1.16M | 3.28M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 21.82M | 40.21M | 56.99M | 72.00M |
| LongTermCapitalLeaseObligation | 21.82M | 40.21M | 56.99M | 72.00M |
| CurrentLiabilities | 82.21M | 81.16M | 67.95M | 62.63M |
| CurrentDebtAndCapitalLeaseObligation | 18.39M | 16.78M | 15.01M | 13.66M |
| CurrentCapitalLeaseObligation | 18.39M | 16.78M | 15.01M | 13.66M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 27.26M | 29.93M | 23.23M | 18.11M |
| PayablesAndAccruedExpenses | 36.55M | 34.44M | 29.71M | 30.86M |
| CurrentAccruedExpenses | 18.20M | 16.93M | 19.93M | 12.24M |
| Payables | 18.36M | 17.51M | 9.78M | 18.62M |
| TotalTaxPayable | 0.00 | 871.00K | 0.00 | |
| IncomeTaxPayable | 0.00 | 871.00K | 0.00 | |
| AccountsPayable | 18.36M | 16.64M | 9.78M | 18.62M |
| TotalAssets | 1.30B | 1.66B | 937.12M | 1.24B |
| TotalNonCurrentAssets | 355.17M | 697.60M | 103.28M | 405.95M |
| OtherNonCurrentAssets | 3.93M | 4.72M | 4.06M | 3.96M |
| InvestmentsAndAdvances | 310.01M | 638.32M | 29.43M | 313.87M |
| InvestmentinFinancialAssets | 310.01M | 638.32M | 29.43M | 313.87M |
| AvailableForSaleSecurities | 310.01M | 638.32M | 29.43M | 313.87M |
| NetPPE | 41.23M | 54.55M | 69.79M | 88.12M |
| AccumulatedDepreciation | -60.12M | -56.50M | -52.23M | -50.07M |
| GrossPPE | 101.34M | 111.05M | 122.02M | 138.19M |
| Leases | 37.52M | 37.52M | 37.28M | 37.28M |
| ConstructionInProgress | 2.75M | 897.00K | 608.00K | 657.00K |
| OtherProperties | 17.57M | 17.53M | 17.43M | 23.18M |
| MachineryFurnitureEquipment | 13.06M | 12.23M | 12.29M | 11.94M |
| BuildingsAndImprovements | 30.45M | 42.88M | 54.41M | 65.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 942.05M | 965.60M | 833.84M | 832.77M |
| OtherCurrentAssets | 44.13M | 40.16M | 35.02M | 38.95M |
| AssetsHeldForSaleCurrent | 0.00 | |||
| PrepaidAssets | 39.84M | |||
| Inventory | 32.92M | 27.62M | 19.08M | 8.49M |
| FinishedGoods | 2.58M | 3.02M | 1.46M | 942.00K |
| WorkInProcess | 30.25M | 24.51M | 17.57M | 7.55M |
| RawMaterials | 88.00K | 89.00K | 51.00K | 0.00 |
| Receivables | 10.58M | 4.11M | 2.81M | 2.21M |
| OtherReceivables | 4.38M | |||
| AccountsReceivable | 10.58M | 4.11M | 2.81M | 2.21M |
| CashCashEquivalentsAndShortTermInvestments | 854.42M | 893.71M | 776.93M | 783.12M |
| OtherShortTermInvestments | 765.29M | 817.46M | 688.72M | 643.86M |
| CashAndCashEquivalents | 89.13M | 76.25M | 88.20M | 139.26M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -387.29M | -391.53M | -314.56M | -314.36M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -802.49M | |
| RepaymentOfDebt | 0.00 | 0.00 | -331.00K | -578.00K |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -14.32M | -1.69M | -18.50M | -4.88M |
| IncomeTaxPaidSupplementalData | 628.00K | 43.15M | 1.57M | 0.00 |
| EndCashPosition | 89.13M | 76.25M | 88.20M | 139.26M |
| BeginningCashPosition | 76.25M | 88.20M | 139.26M | 203.13M |
| ChangesInCash | 12.88M | -11.96M | -51.05M | -63.87M |
| FinancingCashFlow | 8.68M | 14.44M | 5.43M | 2.35M |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | 8.68M | 14.44M | 5.43M | 2.35M |
| ProceedsFromStockOptionExercised | 8.68M | 14.44M | 5.43M | 2.68M |
| NetCommonStockIssuance | 0.00 | 0.00 | -802.49M | |
| CommonStockPayments | 0.00 | 0.00 | -802.49M | |
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -331.00K | -578.00K |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -331.00K | -578.00K |
| LongTermDebtPayments | 0.00 | 0.00 | -331.00K | -578.00K |
| InvestingCashFlow | 377.18M | 363.44M | 239.57M | 243.26M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | 1.80B | |
| CashFlowFromContinuingInvestingActivities | 377.18M | 363.44M | 239.57M | 243.26M |
| NetOtherInvestingChanges | 131.78M | |||
| NetInvestmentPurchaseAndSale | 391.50M | -724.05M | 256.75M | 115.39M |
| SaleOfInvestment | 1.03B | 818.38M | 674.68M | 1.15B |
| PurchaseOfInvestment | -641.76M | -1.54B | -417.93M | -1.03B |
| NetBusinessPurchaseAndSale | 0.00 | 1.09B | 0.00 | 131.78M |
| SaleOfBusiness | 0.00 | 1.09B | 0.00 | 131.78M |
| NetIntangiblesPurchaseAndSale | -10.00M | 0.00 | -17.50M | 0.00 |
| PurchaseOfIntangibles | -10.00M | 0.00 | -17.50M | 0.00 |
| NetPPEPurchaseAndSale | -4.32M | -1.65M | 326.00K | -3.92M |
| SaleOfPPE | 0.00 | 40.00K | 1.32M | 964.00K |
| PurchaseOfPPE | -4.32M | -1.69M | -999.00K | -4.88M |
| OperatingCashFlow | -372.98M | -389.84M | -296.06M | -309.48M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -93.23M | |
| CashFlowFromContinuingOperatingActivities | -372.98M | -389.84M | -296.06M | -309.48M |
| ChangeInWorkingCapital | -33.04M | -19.77M | -19.06M | -16.43M |
| ChangeInOtherCurrentLiabilities | -17.57M | -15.28M | -15.79M | -7.83M |
| ChangeInPayablesAndAccruedExpense | -527.00K | 11.17M | 4.08M | 1.82M |
| ChangeInAccruedExpense | -1.40M | 3.69M | 12.82M | -1.62M |
| ChangeInPayable | 875.00K | 7.47M | -8.73M | 3.44M |
| ChangeInAccountPayable | 1.75M | 6.60M | -8.73M | 3.44M |
| ChangeInTaxPayable | -871.00K | 871.00K | 0.00 | 0.00 |
| ChangeInIncomeTaxPayable | -871.00K | 871.00K | 0.00 | 0.00 |
| ChangeInPrepaidAssets | -3.17M | -5.81M | 3.83M | -176.00K |
| ChangeInInventory | -5.30M | -8.54M | -10.58M | -8.49M |
| ChangeInReceivables | -6.47M | -1.30M | -604.00K | -1.76M |
| ChangesInAccountReceivables | -6.47M | -1.30M | -604.00K | -2.21M |
| OtherNonCashItems | 22.43M | -877.61M | 28.22M | -117.86M |
| StockBasedCompensation | 52.55M | 42.85M | 44.77M | 49.30M |
| AmortizationOfSecurities | -7.20M | -14.49M | -5.05M | -1.20M |
| DepreciationAmortizationDepletion | 5.18M | 5.65M | 6.62M | 8.56M |
| DepreciationAndAmortization | 5.18M | 5.65M | 6.62M | 8.56M |
| OperatingGainsLosses | -113.00K | -200.21M | 525.00K | -48.00K |
| GainLossOnInvestmentSecurities | -118.00K | -167.00K | -28.00K | |
| GainLossOnSaleOfPPE | 5.00K | -39.00K | 553.00K | -48.00K |
| GainLossOnSaleOfBusiness | 0.00 | -200.00M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -412.78M | 673.73M | -352.09M | -231.80M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AGIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|